Concarlo has exclusively licensed and is developing two exciting new technologies: IpY, a therapeutic to specifically combat drug resistance in Cyclin Dependent Kinases (CDK) induced cancers and ApY, an anti-body based kit that can stratify patients' responsiveness to CDK inhibiting therapies. Concarlo has completed significant proof of concept milestones with an exit strategy focused on out-licensing partnerships or acquisition.